WCLC24 Highlights by Oncology Brothers

Oncology Brothers shared on X:

“WCLC24 Highlights Community Oncology:

1. HARMONi2 in mNSCLC
2. CM77TvsCM816 resectable NSCLC
3. TROPIONLung01 in 2L mNSCLC
4. SKIPPirr: AEs for Amivantamab
5. TNM staging: 9th Ed
6. Personal highlights

1. HARMONi2: 1L ivonescimab (PD1/VEGF bispecific) mNSCLC PDL1 ≥ 1% vs Pembro alone.

• mPFS of 11.14 vs 5.8 months
• Increased PFS for PDL1 ≥ 50% (HR: 0.46)
• Increased PFS for PDL1 1-49% (HR: 0.54), but Standard of Care is Pembro + Chemo (no single agent Pembro)
• China only study, will need global study

2. CM816 vs CM77T: NeoAdjuvant Chemo + IO vs PeriOperative Chemo + IO —> Cut —> PostOperative IO (exploratory analysis).

• No head-to-head trial to appreciate the true benefit of post-operative IO.
• Benefit of PostOperative IO mainly in patients with no pathological complete response and/or PDL1 < 1%.

3. TROPIONLung01: 2L and beyond DatoDXd vs Docetaxel for mNSCLC

• All comers: median PFS 4.4 vs 3.7 months and median OS 12.9 vs 11.8 months
• Median OS ‘did not reach statistical significance.’ Docetaxel remains Standard of Care.
• Non-Small Cell Lung Cancer: median PFS 5.5 vs 3.6 months. Median OS 14.6 vs 12.3 months (HR 0.84)
• Grade 3 or greater adverse events better with DatoDXd

4. SKIPPirr: Premedication to reduce Amivantamab-associated infusion reactions. Dexamethasone 8 mg twice daily on Days -2, -1, and 1 dose on Cycle 1 Day 1:

• Reduced infusion reactions with prophylactic dexamethasone.
• Small study. Subcutaneous formulation is pending approval.
• Prophylactic dexamethasone to be used for patients receiving Amivantamab!

5. Proposed 9th Edition during WCLC23 but now part of our practice.

• N1 disease = at least Stage IIA, but some N2 disease can be Stage IIB. N2 is now categorized as N2a (single station) or N2b (multi-station).
• M1c1 vs M1c2

6. Personal Highlights: Seeing Jill Feldman, Amy C. Moore, and colleagues (fellows, students, residents, and thoracic oncologists) from around the world, and moderating a session with phenomenal faculty focusing on Standard of Care and research from WCLC24 in lung cancer.

Source: Oncology Brothers/X

More posts featuring WCLC24 on oncodaily.com
For other posts featuring Oncology Brothers click here.

Drs. Rohit Gosain and Rahul Gosain (aka Oncology Brothers), are medical oncologists/hematologists. Through their social media platforms like X/Twitter, they actively engage with their audience. With their own YouTube channel and podcast, they provide accessible resources for cancer patients and their families.

Additionally, their participation in live conferences ensures that cancer patients receive the best care closer to home, reflecting their commitment to advancing oncology and improving patient outcomes through education and outreach.